Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -39.76% is 16% below its 5-year average of -34.25%, around the middle of its 5-year range (-58.22%–-16.72%).
52.92% below its 12-month average of -26.00%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -12.30%.
RETURN ON ASSETS (ROA)
-39.76%
RETURN ON ASSETS (ROA) AVG TTM
-26.00%
RETURN ON ASSETS (ROA) AVG 3Y
-40.35%
RETURN ON ASSETS (ROA) AVG 5Y
-34.25%
RETURN ON ASSETS (ROA) AVG 10Y
-63.08%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-52.92%
CURRENT VS 3Y AVG
+1.47%
CURRENT VS 5Y AVG
-16.08%
CURRENT VS 10Y AVG
+36.97%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.24%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-23.33%
vs the sector median at left
Protara Therapeutics, Inc.
Market Cap
$143.60M
Return on Assets (ROA)
-39.76%
TTM Avg
-26.00%
3Y Avg
-40.35%
5Y Avg
-34.25%
Market Cap
$143.84M
Return on Assets (ROA)
-76.12%
TTM Avg
-156.63%
3Y Avg
-142.29%
5Y Avg
-134.64%
Market Cap
$143.10M
Return on Assets (ROA)
-59.36%
TTM Avg
-56.73%
3Y Avg
-42.41%
5Y Avg
-32.43%
Market Cap
$146.27M
Return on Assets (ROA)
35.31%
TTM Avg
-14.11%
3Y Avg
-23.46%
5Y Avg
-20.68%
Market Cap
$146.28M
Return on Assets (ROA)
-25.59%
TTM Avg
-36.78%
3Y Avg
-35.70%
5Y Avg
-27.05%
Market Cap
$146.62M
Return on Assets (ROA)
-90.55%
TTM Avg
-70.80%
3Y Avg
-45.07%
5Y Avg
-40.08%
Market Cap
$139.84M
Return on Assets (ROA)
-92.89%
TTM Avg
-84.34%
3Y Avg
-55.16%
5Y Avg
-43.29%
Market Cap
$139.47M
Return on Assets (ROA)
-36.33%
TTM Avg
-27.39%
3Y Avg
-256.74%
5Y Avg
-207.88%
Market Cap
$139.04M
Return on Assets (ROA)
-28.35%
TTM Avg
-69.97%
3Y Avg
-58.34%
5Y Avg
-49.63%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | $143.60M | -39.76% | -26.00% | -40.35% | -34.25% |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $143.84M | -76.12% | -156.63% | -142.29% | -134.64% |
| Nyxoah S.A. (NYXH)vs › | $143.10M | -59.36% | -56.73% | -42.41% | -32.43% |
| Fortress Biotech, Inc. (FBIOP)vs › | $146.27M | 35.31% | -14.11% | -23.46% | -20.68% |
| Codexis, Inc. (CDXS)vs › | $146.28M | -25.59% | -36.78% | -35.70% | -27.05% |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $146.62M | -90.55% | -70.80% | -45.07% | -40.08% |
| Sutro Biopharma, Inc. (STRO)vs › | $139.84M | -92.89% | -84.34% | -55.16% | -43.29% |
| Alpha Cognition Inc (ACOG)vs › | $139.47M | -36.33% | -27.39% | -256.74% | -207.88% |
| Immuneering Corporation (IMRX)vs › | $139.04M | -28.35% | -69.97% | -58.34% | -49.63% |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.27M | -20.01% | -38.20% | -34.64% | -39.69% |
ROA
-39.8%
ROE
-43.4%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -27.42% |
| 2024-12-31 | -24.58% |
| 2023-12-31 | -51.19% |
| 2022-12-31 | -58.22% |
| 2021-12-31 | -27.38% |
| 2020-12-31 | -16.72% |
| 2019-12-31 | -214.94% |
| 2018-12-31 | -108.15% |
| 2017-12-31 | -68.13% |
| 2016-12-31 | -65.55% |
| 2015-12-31 | -31.65% |
| 2014-12-31 | -3.94% |
| 2013-12-31 | -139.81% |
| 2012-12-31 | -102.42% |
